Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Pyruvate Nasal Spray (N115) for Long COVID Symptoms
NCT04871815Phase 3Completed
- Sponsor
- Cellular Sciences
- Start
- Apr 2021
- Primary completion
- Mar 2022
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sodium pyruvate nasal spray in post-acute sequelae of SARS-CoV-2 infection (PASC), sponsored by Cellular Sciences. Primary endpoints: Change in the Symptoms of Long COVID-19 Patients at 14 days, Change in Body Temperature in Long COVID-19 Patients at 14 days and 2 more. Started Apr 2021; status: completed.
02
Drugs
sodium pyruvate nasal spray
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT04871815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04871815.